Drug Profile
Polysaccharide A - Symbiotix Biotherapies
Alternative Names: PSA - Symbiotix Biotherapies; Reglemers™; SYMB 104; ZPS therapeutic - Symbiotix; Zwitterionic polysaccharide - SymbiotixLatest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Symbiotix Biotherapies
- Developer Geisel School of Medicine; Symbiotix Biotherapies
- Class Antibacterials; Polysaccharides
- Mechanism of Action CD4-positive T-lymphocyte modulators; Immunomodulators; Interleukin-10 expression stimulants; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory bowel diseases; Multiple sclerosis
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA (PO)
- 28 Jul 2019 No recent reports of development identified for research development in Multiple-sclerosis in USA (PO)
- 21 Mar 2018 Symbiotix Biotherapies in-licenses intellectual property from Harvard University